Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 7/20 | 0.82 |
| ▸ | MEN1 | O00255 | 4/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.73 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.64 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 4/20 | 0.63 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.63 |
| ▸ | USP2 | O75604 | 2/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17276464 | 0.89 | NCF1 (0.79) | NCF1MEN1KMT2AADRB2ADRB1 | |
| SCHEMBL21392990 | 0.87 | MEN1 (0.78) | NCF1MEN1KMT2AADRB2ADRB1 | |
| SCHEMBL15277916 | 0.87 | NCF1 (0.75) | NCF1MEN1KMT2AADRB2ADRB1 | |
| SCHEMBL5523102 | 0.85 | NCF1 (0.72) | NCF1MEN1KMT2AADRB2ADRB1 | |
| SCHEMBL5065450 | 0.84 | NCF1 (0.88) | NCF1MEN1KMT2AADRB2ADRB1 | |
| SCHEMBL4178112 | 0.83 | NCF1 (0.59) | NCF1MEN1KMT2A | |
| SCHEMBL6125246 | 0.82 | NCF1 (0.75) | NCF1MEN1KMT2AADRB2ADRB1 | |
| SCHEMBL30511704 | 0.82 | NCF1 (0.97) | NCF1MEN1KMT2AADRB2ADRB1 | |
| SCHEMBL15152938 | 0.82 | MEN1 (0.78) | NCF1MEN1KMT2AADRB2ADRB1 | |
| SCHEMBL5530017 | 0.82 | NCF1 (0.67) | NCF1MEN1KMT2AADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621923-B1 | N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES | INTERVET INT BV (NL) | 2017-03-29 | — | — | EP | disclosed |
| EP-2828253-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | Abide Therapeutics, Inc. (US) | 2015-01-28 | — | — | EP | disclosed |
| US-8883791-B2 | N-heteroaryl compounds with cyclic bridging unit for the treatment of parasitic diseases | INTERVET INC. (US) | 2014-11-11 | — | — | US | disclosed |
| WO-2013142307-A1 | CARBAMATE COMPOUNDS AND OF MAKING AND USING SAME | ABIDE THERAPEUTICS (US) | 2013-09-26 | — | — | WO | disclosed |
| US-20130203768-A1 | N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES | INTERVET INC. | 2013-08-08 | — | — | US | disclosed |
| EP-2621923-A1 | N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES | Intervet International B.V. (NL) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012041872-A1 | N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES | INTERVET INTERNATIONAL B.V. (NL) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203768-A1 | N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES | PIGO, HNMT, PIGS | NCF1 823/4885MEN1 1483/4885KMT2A 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.